title: HIV-Associated Gastrointestinal Cancer.
abstract: People living nowadays with HIV and AIDS may be treated effectively regarding virus replication and immunology. However, non-AIDS-defining cancer is of growing relevance due to high incidence and unfavorable outcome. The aim of this review is to summarize current knowledge on gastrointestinal (GI) carcinoma. Although literature on GI cancer is rare, an increased incidence of esophageal, gastric, pancreatic, hepatocellular, and colorectal carcinoma has been demonstrated. However, there are only few reports on therapy strategies and outcome, so that, despite increased occurrence of many GI carcinomas, only little is known about individualized treatment options and outcome in HIV-positive patients. More efforts have to be undertaken to close this gap.
authors.forename: Björn E-O
authors.initials: BE
authors.lastname: Jensen
authors.forename: Mark
authors.initials: M
authors.lastname: Oette
authors.forename: Johannes
authors.initials: J
authors.lastname: Haes
authors.forename: Dieter
authors.initials: D
authors.lastname: Häussinger
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000379:methods / Q000592:standards; D019317:Evidence-Based Medicine; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008495:Medical Oncology / Q000592:standards; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D000970:Antineoplastic Agents